Drug Interactions between Erythromycin and Statins

Introduction to Erythromycin and Statin Interaction

• Erythromycin is a potent inhibitor of the cytochrome P450 enzyme system, specifically the CYP3A4 subclass, which is responsible for the metabolism of many statins, according to the American Heart Association 1
• The interaction between erythromycin and statins can lead to reduced cholesterol-lowering efficacy and increased risk of statin toxicity, as reported by the Centers for Disease Control and Prevention 2

Mechanism of Interaction

• Erythromycin inhibits CYP3A4-mediated metabolism of statins like atorvastatin, lovastatin, and simvastatin, which can affect their pharmacokinetics, as stated by the American College of Cardiology 1
• Erythromycin also inhibits P-glycoprotein (P-gp) transport and organic anion-transporting polypeptide (OATP1B1 and OATP1B3), further affecting statin pharmacokinetics, according to the National Institutes of Health 1

Clinical Recommendations

• The American Heart Association recommends avoiding concurrent use of erythromycin with lovastatin, simvastatin, and atorvastatin whenever possible, due to the high risk of adverse effects 1, 2
• If co-administration cannot be avoided, the Centers for Disease Control and Prevention suggest reducing statin dosage by approximately 50-80% during erythromycin treatment and monitoring for signs of statin toxicity 2

Other Interactions and Considerations

• Erythromycin also interacts with numerous other medications through the same CYP3A4 inhibition mechanism, which can lead to significant interindividual variability in drug response, as reported by the Journal of Clinical Pharmacology 2, 3
• Patients with renal or hepatic impairment may be at higher risk for adverse effects from this interaction, according to the National Kidney Foundation 2